IL173405A - Compositions for infusion containing ex-vivo prepared t-cells and methods for the preparation thereof - Google Patents

Compositions for infusion containing ex-vivo prepared t-cells and methods for the preparation thereof

Info

Publication number
IL173405A
IL173405A IL173405A IL17340506A IL173405A IL 173405 A IL173405 A IL 173405A IL 173405 A IL173405 A IL 173405A IL 17340506 A IL17340506 A IL 17340506A IL 173405 A IL173405 A IL 173405A
Authority
IL
Israel
Prior art keywords
cells
infusion
composition
methods
container
Prior art date
Application number
IL173405A
Other languages
English (en)
Other versions
IL173405A0 (en
Original Assignee
Immunovative Therapies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies Ltd filed Critical Immunovative Therapies Ltd
Publication of IL173405A0 publication Critical patent/IL173405A0/en
Publication of IL173405A publication Critical patent/IL173405A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
IL173405A 2004-03-01 2006-01-29 Compositions for infusion containing ex-vivo prepared t-cells and methods for the preparation thereof IL173405A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54903204P 2004-03-01 2004-03-01
PCT/US2005/006446 WO2005084276A2 (en) 2004-03-01 2005-03-01 Cell therapy formulation method and composition

Publications (2)

Publication Number Publication Date
IL173405A0 IL173405A0 (en) 2006-06-11
IL173405A true IL173405A (en) 2011-02-28

Family

ID=34919427

Family Applications (3)

Application Number Title Priority Date Filing Date
IL173405A IL173405A (en) 2004-03-01 2006-01-29 Compositions for infusion containing ex-vivo prepared t-cells and methods for the preparation thereof
IL210244A IL210244A0 (en) 2004-03-01 2010-12-23 Compositions for infusion containing activated t- cells
IL223938A IL223938B (en) 2004-03-01 2012-12-27 Compositions for infusion containing ex-vivo prepared t-cells and methods for the preparation thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL210244A IL210244A0 (en) 2004-03-01 2010-12-23 Compositions for infusion containing activated t- cells
IL223938A IL223938B (en) 2004-03-01 2012-12-27 Compositions for infusion containing ex-vivo prepared t-cells and methods for the preparation thereof

Country Status (10)

Country Link
EP (2) EP1749090B1 (enExample)
JP (3) JP5144250B2 (enExample)
CA (1) CA2530514C (enExample)
DK (1) DK1749090T3 (enExample)
ES (1) ES2635868T3 (enExample)
HU (1) HUE035726T2 (enExample)
IL (3) IL173405A (enExample)
PL (1) PL1749090T3 (enExample)
PT (1) PT1749090T (enExample)
WO (1) WO2005084276A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
SI2573166T1 (sl) 2004-02-26 2016-09-30 Immunovative Therapies, Ltd. Metode za pripravo T-celic za celično terapijo
PH12013502252B1 (en) 2011-05-03 2018-09-21 Immunovative Therapies Ltd Induction of il-12 using immunotherapy
KR102202460B1 (ko) 2011-05-03 2021-01-14 이뮤노베이티브 테라피스, 엘티디. 생세포를 포함하는 생물학적 약물을 처리하기 위한 방법
WO2015105999A1 (en) * 2014-01-08 2015-07-16 Immunovative Therapies, Ltd. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
WO1988000970A2 (en) 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
WO1994012196A1 (en) * 1992-11-25 1994-06-09 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
WO1994029436A1 (en) * 1993-06-04 1994-12-22 The United States Of America Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
EP0726941B1 (en) 1993-08-06 2002-04-03 Epimmune Inc. Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
CA2191586A1 (en) * 1994-06-03 1995-12-14 Carl H. June Methods for selectively stimulating proliferation of t cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
EP0814838B1 (en) 1995-03-08 2003-05-14 The Scripps Research Institute Antigen presenting system and activation of t-cells
JP2002515756A (ja) 1997-01-31 2002-05-28 ヘモソル インク． 選択されたリンパ球の生産方法
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US20040258661A1 (en) * 2001-10-31 2004-12-23 Daniel Fowler Generation of use of tc1 and tc2 cells
AU2003202908A1 (en) * 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
SI2573166T1 (sl) * 2004-02-26 2016-09-30 Immunovative Therapies, Ltd. Metode za pripravo T-celic za celično terapijo

Also Published As

Publication number Publication date
WO2005084276A3 (en) 2007-05-10
PL1749090T3 (pl) 2017-12-29
EP1749090A4 (en) 2009-04-29
ES2635868T3 (es) 2017-10-05
JP5144250B2 (ja) 2013-02-13
EP1749090A2 (en) 2007-02-07
WO2005084276A2 (en) 2005-09-15
JP2007526314A (ja) 2007-09-13
IL223938B (en) 2020-01-30
JP5649551B2 (ja) 2015-01-07
JP2014077018A (ja) 2014-05-01
HUE035726T2 (en) 2018-05-28
DK1749090T3 (en) 2017-09-04
IL210244A0 (en) 2011-03-31
JP2012021033A (ja) 2012-02-02
PT1749090T (pt) 2017-08-28
CA2530514C (en) 2017-01-31
CA2530514A1 (en) 2005-09-15
EP1749090B1 (en) 2017-05-17
EP3202895A1 (en) 2017-08-09
IL173405A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
US8778678B2 (en) Composition of activated CD4 cells
US7402431B2 (en) T-cell therapy formulation
EP2900809B1 (en) Method for polyclonal stimulation of t cells by mobile nanomatrices
Kim et al. TLR7/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based cancer immunotherapy
US20100028450A1 (en) Tolerogenic biodegradable artificial antigen presenting system
ES2586295T3 (es) Los métodos para preparar las células T para la terapia celular
Steenblock et al. Antigen presentation on artificial acellular substrates: modular systems for flexible, adaptable immunotherapy
ZA200309435B (en) Re-activated T-cells for adoptive immunotherepay
EP2590679B1 (en) Immunomodulatory protein constructs with a helical polymeric backbone
WO2013036585A1 (en) Activation and expansion of t cell subsets using biocompatible solid substrates with tunable rigidity
JP5649551B2 (ja) 細胞治療処方方法および組成物
Nguyen et al. Strategies to Design and Optimize Artificial Antigen‐Presenting Cells for T Cell Expansion in Cancer Immunotherapy
CN108245673A (zh) 表达Th1特性和溶细胞性质的细胞
Weiden et al. Robust antigen-specific T cell activation within injectable 3D synthetic nanovaccine depots
JP3951350B2 (ja) リンパ球細胞の製造法及び免疫治療剤
Knolle Cognate interaction between endothelial cells and T cells
WO2025174838A1 (en) Compositions of an artificial lymph node matrix and methods of preparing the same
Verneris et al. EX VIVO activated and expanded CD8+ T cells recognize malignant cells through a TCR independent and NKG2D dependent pathway
Doubrovina et al. Characterization of the tumor-specific activity of WT1 specific T cells generated in vitro from normal individuals by sensitization with WT1-peptide loaded autologous EBV transformed B cells

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed